Altimmune 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Altimmune reported Q3 2026 R&D expense of $27 million, compared with $15 million in the same period prior year, including $20.3 million of direct costs related to pemvedutide development.
- Q3 2026 G&A expenses were $8.7 million, compared with $5.9 million in the same period prior year; net loss was $31.6 million, or $0.15 a share, compared with $19 million, or $0.21 a share, in Q3 2025.
- Altimmune ended the quarter with $480 million in cash, cash equivalents, and investments.
- Management said the global PERFORMER Phase 3 NASH trial is screening and dosing patients, with over 70 U.S. sites activated and recruiting; ex-U.S. site activations are expected to begin over the coming months.
- The company said new analyses from the 48-week IMPACT Phase 2b trial showed concurrent improvements across multiple noninvasive measures of liver fat, inflammation, and fibrosis, with generally favorable tolerability.
- RECLAIM Phase 2 results showed statistically significant improvements in heavy drinking days, WHO risk drinking level, and achievement of zero heavy drinking days; PETH corroborated self-reported reductions in alcohol intake.
- RESTORE enrolled 121 patients with ALD and a history of chronic and heavy drinking at baseline.
- Management said the IMPACT Phase 2b 48-week efficacy and safety data were published in The Lancet.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the Altimmune third quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. As a reminder, this call is being recorded. I will now introduce your host for today's conference call, Luis Sanay, Vice President of Investor Relations.
Luis, you may begin. Thank you, operator, and good morning, everyone.
Thank you for joining us for Altimmune's third quarter 2026 financial results and business update call. On today's call, you will hear from Jerry Durso, our Chairman and Chief Executive Officer, Dr. Christophe Arbet-Engels, Chief Medical Officer, Linda Richardson, Chief Commercial Officer, and Greg Weaver, Chief Financial Officer. Following management's prepared remarks, we will open the line for questions. Our third quarter 2026 earnings release was issued this morning and can be found on the Investor Relations section of our website. Before we begin, I would like to remind everyone that remarks made about future expectations, plans, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.
For a review of the risk factors that could affect the company's future results and operations, we refer you to our SEC filings. I also direct you to read the forward-looking statements disclaimer in our press release issued this morning. Any statements made on this call speak only as of today's date, November 12, 2026, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this call is being recorded and will be available for audio replay on our website. With that, I will now turn the call over to Jerry.
Good morning, everyone, and thank you for joining us today. We enter the final months of the year with strong confidence in pemvidutide and the strategy we are laser-focused on executing. Over the course of this year, we significantly advanced our programs across the board in MASH, AUD, and ALD, further strengthening our belief that pemvidutide's differentiated clinical profile can support a broad liver franchise with multiple indications in serious liver diseases. We are now focused on carrying that momentum forward through disciplined execution. We continue to see a growing understanding and scientific support for the potential therapeutic role of Pemvi and its ability to provide meaningful benefit to people affected by serious liver diseases. Our conviction in pemvidutide is stronger than ever coming out of AASLD's The Liver Meeting, where the data presented further validates the potential of pemvidutide and our overall development strategy.
MASH data presented at several podium talks at the meeting reinforced the potential of the dual glucagon GLP-1 mechanism in MASH and underscored the differentiation of pemvidutide. We presented new NIT data from our 48-week IMPACT study that highlighted the strong anti-fibrotic activity of Pemvi that continues to compare favorably to data across other trials. We believe pemvidutide's balanced 1:1 glucagon to GLP-1 ratio, when coupled with our proprietary EuPort domain, matters and results in a molecule that balances metabolic and liver-directed activity with generally favorable tolerability. Despite new products entering the MASH field and others in various stages of development, there remains a significant unmet need for patients, and we believe that pemvidutide could represent a well-differentiated MASH therapy. We see a major commercial opportunity across the indications we're targeting as we build our liver franchise.
In addition to the unmet need in MASH, we view AUD and ALD as part of a patient continuum, as AUD patients often progress to liver impairment. In fact, data referenced at The Liver Meeting estimates that 55%-94% of ALD patients also meet the criteria for AUD. The RECLAIM data highlighted that Pemvi has the potential to help address both alcohol consumption and the liver damage that can result from it. Finally, one of the recurring themes at The Liver Meeting was about the overlap of MASH and alcohol use. We believe pemvidutide's differentiated profile positions it well across a multitude of patients. Moving now on to execution, which is a critical focus for Altimmune. First, our global PERFORMA phase III trial is ramping up, and we're very encouraged by the progress to date.
Clinical trial sites continue to come online according to our plan, and we're actively enrolling patients. The engagement we see from the PERFORMA investigators and the broader MASH community is strong. This excitement was quite evident at The Liver Meeting, and Christophe will touch on the positive feedback and engagement from KOLs on PERFORMA and pemvidutide overall. We're also pleased that the IMPACT phase IIb 48-week efficacy and safety data was published in The Lancet this week. In AUD, the positive RECLAIM phase II data were highlighted in a late-breaking oral presentation. We believe this is the most robust AUD data presented to date. The strong results we saw significantly de-risk this program. Importantly, our end-of-phase II meeting with the FDA is scheduled for next month, representing a key step towards advancing pemvidutide in AUD.
We look forward to engaging with the agency and continuing our progress of Pemvi in this indication. As part of our continued evolution as a late-stage biotech company, we're also thrilled to recently have added Peter Greenleaf and Alex Howarth to our board of directors. Peter and Alex are accomplished industry leaders that bring a breadth of experience across drug development, commercialization, and corporate development. Their experience and strategic perspectives will be valuable to Altimmune as we continue to advance. In summary, we're committed to executing our strategy with speed and efficiency reflected in the significant progress we've made across the pemvidutide franchise this year. We're laser-focused on delivering on our goals of bringing a differentiated therapy in Pemvi to patients and creating value for our shareholders. Our conviction in pemvidutide is stronger than ever, and we look forward to sharing our continued progress.
I'll now turn the call over to Christophe for a clinical update.
Thank you, Gary. I'd like to start by just stating that I am very pleased with the significant progress we are making as we advance our clinical programs across MASH, AUD, and ALD. Beginning with MASH, the global PERFORMA phase III trial is underway and progressing as planned. We are screening and dosing patients, and clinical site activation continues across the program as we build towards broader global enrollment. We have the majority of planned U.S. sites now active and recruiting patients, and we expect to activate the ex-U.S. sites over the coming months. We will continue to work closely with our CRO partner to support efficient trial execution and enrollment. Overall, we remain encouraged by the enthusiasm and engagement we are seeing from investigators and clinical sites for PERFORMA based on the product profile and the efficient trial design.
As a reminder, we anticipated the PERFORMA 52-week data readout in 2029. Altimmune had a strong presence at the recent Liver Meeting in Denver, where we had the opportunity to highlight the potential of pemvidutide in serious liver diseases. We saw a growing interest and excitement for pemvidutide from the scientific community and the role it may play in treating the liver damage that characterizes the overlapping metabolic and alcohol-associated diseases of MASH, AUD, and ALD. During the Liver Meeting, we presented two analyses from the IMPACT phase IIb trial, including compelling data showing concurrent improvement across multiple non-invasive measures of liver fat, inflammation, and fibrosis compared to patients receiving placebo. The new data further illustrate the strong and consistent anti-fibrotic activity and a generally favorable tolerability profile in the absence of dose titration.
Our data, along with emerging data from other glucagon GLP-1 programs, reinforce the importance of glucagon in treating MASH. The totality of our learning during the Liver Meeting further support our phase III study design. We also hosted a well-attended disease state product theater where Dr. Mazen Noureddin, Dr. Rohit Loomba, and Dr. Jessica Mellinger discussed the advanced liver disease continuum. They noted the prognostic importance of fibrosis on outcomes and how various factors, including alcohol consumption or metabolic dysfunction, impact the progression of serious liver disease. The product theater further underscored the overlap between excessive alcohol consumption and metabolic causes of serious liver disease and the high unmet need for a therapy that can chronically address both causes and their liver damage consequences.
We believe that the data presented on pemvidutide during The Liver Meeting strongly support the potential of pemvidutide to address that unmet need with a generally well-tolerated approach that is particularly suitable for chronic diseases such as MASH, AUD, and ALD. In addition, Dr. Henry Kranzler, the lead investigator for our RECLAIM phase II trial, presented the very robust and positive study results in the late-breaking oral presentation at The Liver Meeting. To our knowledge, the RECLAIM data is the strongest data in AUD to date. The trial showed statistically significant improvements with pemvidutide across the primary endpoint of heavy drinking days, as well as key secondary measures, including WHO-RDL and achievement of zero heavy drinking days, both of which are FDA registrational endpoints. Importantly, we also demonstrated that PEth, an objective serum-based measure of alcohol consumption, corroborated the self-reported reduction in alcohol intake in Pemvi-treated patients.
Pemvidutide also increased abstinence in patients with AUD. While RECLAIM was focused on drinking behaviors, the trial demonstrated in an exploratory analysis that Pemvi decreased the proportion of patients with elevated risk for developing advanced liver fibrosis as measured by FIB-4. These data point towards potential liver improvement in this patient population. Given Pemvi's direct glucagon effect on the liver, the observed data is very encouraging, and we expect to further evaluate the potential liver benefits in the registrational phase III study in AUD, with inclusion of a subpopulation of AUD patients with advanced liver impairment. Importantly, RECLAIM was conducted in patients with moderate to severe AUD, the population we believe may have the greatest need for more effective and safe treatment options, and who are at risk of alcohol-related liver disease.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
